Search Results
Sep 03, 2026, 08:00 ET 40 years in San Diego: Alaska Airlines kicks off anniversary celebration with 50th nonstop destination
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
forward efficiently, Fosun Pharma continues to fuel its long-term commercial growth.- The NDA for SAF-189 (foritinib succinate capsules), an ALK inhibitor for non-small-cell lung cancer, has been accepted by the NMPA.- The NDA of Fu Mai Ning for adult patients with symptomatic, inoperable
More news about: Fosun Pharma
Aug 20, 2026, 23:43 ET Alaska Airlines annonce une nouvelle liaison sans escale vers Athènes et Paris, reliant Seattle à un plus grand nombre de destinations dans le monde
news.alaskaair.com. Alaska Air Group est coté à la bourse de New York (NYSE) sous le code « ALK ».
More news about: Alaska Airlines
Aug 20, 2026, 09:28 ET Alaska Airlines kündigt neue Direktflüge nach Athen und Paris an und verbindet Seattle damit mit weiteren Zielen weltweit
news.alaskaair.com. Die Alaska Air Group wird an der New Yorker Börse (NYSE) unter dem Kürzel „ALK" gehandelt.
More news about: Alaska Airlines
Aug 20, 2026, 08:00 ET Alaska Airlines teams up with world champion Seattle quarterback Sam Darnold to launch multi-year partnership celebrating Seattle, Alaska's loyal guests and its growing global network
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Air Group
Aug 20, 2026, 08:00 ET Alaska Airlines announces new nonstop service to Athens and Paris, connecting Seattle to more of the world
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Aug 20, 2026, 08:00 ET Alaska Airlines announces new nonstop service to Athens and Paris, connecting Seattle to more of the world
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Aug 20, 2026, 08:00 ET Alaska Airlines anuncia un nuevo servicio sin escalas a Atenas y París
news.alaskaair.com. Alaska Air Group cotiza en la Bolsa de Valores de Nueva York (NYSE) con el símbolo "ALK".
More news about: Alaska Airlines
Aug 06, 2026, 10:31 ET The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
Inimmune, Novartis (Excellergy), Intrommune Therapeutics, Regeneron Pharmaceuticals, Sanofi, Moonlight Therapeutics, Mabylon AG, Insignis Therapeutics, ALK-Abello, Cambridge Allergy, Prota Therapeutics, and others.Related Reports
More news about: DelveInsight Business Research, LLP
Jul 30, 2026, 05:09 ET NMPA Accepts New Indication Application for Sacituzumab Tirumotecan (sac-TMT) as First-Line Treatment for Advanced TNBC
treatment for locally advanced or metastatic NSCLC who have PD-L1 tumor proportion score (TPS)≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative; and 2) sac‑TMT as first‑line treatment for patients with recurrent or metastatic TNBC who have a PD‑L1 CPS <10 or have recurred after prior
More news about: Kelun-Biotech
Jul 29, 2026, 08:00 ET Frontier Airlines Delivers Record Second Quarter 2026 Revenue of $1.3 billion, up 38 percent Year-over-Year and Significantly Beats Wall Street Estimates
while keeping fares low.End Notes1 Industry average weighted by ASMs in FY2025 to include DAL, UAL, AAL, LUV, JBLU, ALK, and ALGT. Fuel efficiency is measured by ASMs per fuel gallon consumed.Cautionary Statement Regarding Forward-Looking Statements and InformationCertain
More news about: Frontier Group Holdings, Inc.
Jul 27, 2026, 10:31 ET Food Allergy Market on the Rise: 5 Emerging Therapies to Watch | DelveInsight
pipeline, with key programs being developed by companies such as DBV Technologies (Viaskin [DBV712] Peanut Patch), Novartis (Remibrutinib), Aravax (PVX108), ALK-Abelló (Sublingual Immunotherapy Tablet), InnoUp Farma (INP20), Allergy Therapeutics (VLP Peanut), Intrommune Therapeutics (INT301), Regeneron Pharmaceuticals
More news about: DelveInsight Business Research, LLP
Jul 23, 2026, 10:31 ET ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
ALK Inhibitors Patient Population ForecastALK Inhibitors Therapeutics Market SizeALK Inhibitors Pipeline AnalysisALK Inhibitors Market Size and TrendsALK Inhibitors Market OpportunityALK Inhibitors Market Unmet NeedsKOL's Views on ALK InhibitorsALK
More news about: DelveInsight Business Research, LLP
Jul 22, 2026, 13:58 ET Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer
in lung cancer. The company is advancing additional medicines from the recent Nuvalent acquisition, including neladalkib (NVL-655) for patients with ALK-altered NSCLC, which is currently under FDA review with a target decision date of 27 November 2026, and NVL-330, an investigational treatment for HER2-altered
More news about: GSK plc
Jul 21, 2026, 17:56 ET Alaska Air Group reports second quarter 2026 results
SEATTLE, July 21, 2026 /PRNewswire/ -- Alaska Air Group (NYSE: ALK) today reported financial results for the second quarter ending June 30, 2026.
More news about: Alaska Air Group
Jul 21, 2026, 16:30 ET Alaska Airlines, Inc. doubles cargo capacity with addition of four freighters
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Jul 21, 2026, 16:30 ET Alaska Airlines, Inc. selects 737-800s to strengthen Hawaiian Airlines' Neighbor Island service, enhancing the guest experience and increasing capacity
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines
Jul 14, 2026, 19:30 ET Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
(KEYTRUDA®) as first‑line treatment for locally advanced or metastatic NSCLC who have PD-L1 TPS≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has entered the priority review and approval process. As of today, Kelun-Biotech has initiated 9
More news about: Kelun-Biotech
Jul 09, 2026, 11:00 ET A record Fourth of July and a first-place finish for the first half of 2026: Alaska and Hawaiian lead the industry in performance
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Air Group
Jul 09, 2026, 09:00 ET Alaska Air Group announces webcast of second-quarter 2026 financial results
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Air Group
Jul 08, 2026, 22:16 ET Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
China. Of patients with lung cancer, NSCLC accounts for up to 85%. Approximately 5-7% of patients with NSCLC have ALK-positive disease. Although some patients with ALK-positive NSCLC are diagnosed at an early or intermediate stage amenable to surgical resection, they still face high risks of
More news about: Betta Pharmaceuticals
Jul 02, 2026, 10:31 ET Non-Small Cell Lung Cancer Market Poised for Robust Expansion at a 6.6% CAGR Through 2036, Driven by Emerging Targeted and Immunotherapy Innovations | DelveInsight
Neladalkib is an advanced, brain-penetrant ALK inhibitor with high selectivity, developed to effectively target ALK resistance mutations while minimizing central nervous system toxicities associated with TRK inhibition. Created by Nuvalent for the treatment of ALK-driven malignancies, the therapy is designed
More news about: DelveInsight Business Research, LLP
Jul 02, 2026, 06:30 ET Partner Therapeutics Announces Publication of Results From the eNRGy Trial of Zenocutuzumab in Patients with NRG1+ Cholangiocarcinoma in Journal of Clinical Oncology (JCO)
FusionsNRG1 fusions are unique cancer drivers that create oncogenic chimeric ligands rather than the more widely described chimeric receptors (NTRK, RET, ROS1, ALK, and FGFR fusions). The chimeric ligands bind to HER3, triggering HER2/HER3 heterodimerization and activating downstream signaling pathways
More news about: Partner Therapeutics, Inc.
Jun 30, 2026, 19:00 ET 'Aloha all around the world:' Hawaiian Airlines unveils oneworld alliance livery aircraft featuring ʻŌlelo Hawaiʻi
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Hawaiian Airlines
Jun 25, 2026, 08:00 ET Atmos™ Rewards members now unlock free inflight Wi-Fi on Alaska Airlines and Hawaiian Airlines, thanks to T-Mobile
news.alaskaair.com. Alaska Air Group is traded on the New York Stock Exchange (NYSE) as "ALK."
More news about: Alaska Airlines